These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19268584)

  • 1. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
    Lewis JA; Scott SA; Lavieri R; Buck JR; Selvy PE; Stoops SL; Armstrong MD; Brown HA; Lindsley CW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1916-20. PubMed ID: 19268584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.
    Lavieri R; Scott SA; Lewis JA; Selvy PE; Armstrong MD; Alex Brown H; Lindsley CW
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2240-3. PubMed ID: 19299128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further evaluation of novel structural modifications to scaffolds that engender PLD isoform selective inhibition.
    O'Reilly MC; Scott SA; Brown HA; Lindsley CW
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5553-5557. PubMed ID: 25466173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoform selective PLD inhibition by novel, chiral 2,8-diazaspiro[4.5]decan-1-one derivatives.
    Waterson AG; Scott SA; Kett NR; Blobaum AL; Alex Brown H; Lindsley CW
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3670-3673. PubMed ID: 30528979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
    Noble AR; Maitland NJ; Berney DM; Rumsby MG
    Br J Cancer; 2018 Jan; 118(2):189-199. PubMed ID: 29136407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two sites of action for PLD2 inhibitors: The enzyme catalytic center and an allosteric, phosphoinositide biding pocket.
    Ganesan R; Mahankali M; Alter G; Gomez-Cambronero J
    Biochim Biophys Acta; 2015 Mar; 1851(3):261-72. PubMed ID: 25532944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
    Lavieri RR; Scott SA; Selvy PE; Kim K; Jadhav S; Morrison RD; Daniels JS; Brown HA; Lindsley CW
    J Med Chem; 2010 Sep; 53(18):6706-19. PubMed ID: 20735042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Insights for Drugs Developed for Phospholipase D Enzymes.
    Stieglitz KA
    Curr Drug Discov Technol; 2018; 15(2):81-93. PubMed ID: 28814238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of halopemide for phospholipase D2 inhibition.
    Monovich L; Mugrage B; Quadros E; Toscano K; Tommasi R; LaVoie S; Liu E; Du Z; LaSala D; Boyar W; Steed P
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2310-1. PubMed ID: 17317170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis.
    Su W; Yeku O; Olepu S; Genna A; Park JS; Ren H; Du G; Gelb MH; Morris AJ; Frohman MA
    Mol Pharmacol; 2009 Mar; 75(3):437-46. PubMed ID: 19064628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the formation rate of phosphatidylethanol by phospholipase D (PLD) in blood and test of two selective PLD inhibitors.
    Schröck A; Henzi A; Bütikofer P; König S; Weinmann W
    Alcohol; 2018 Dec; 73():1-7. PubMed ID: 30103144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcellular distribution and characterization of rat pancreatic phospholipase D isoforms.
    Lainé J; Bourgoin S; Bourassa J; Morisset J
    Pancreas; 2000 May; 20(4):323-36. PubMed ID: 10824686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke--brief report.
    Stegner D; Thielmann I; Kraft P; Frohman MA; Stoll G; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2212-7. PubMed ID: 23868933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
    Scott SA; Spencer CT; O'Reilly MC; Brown KA; Lavieri RR; Cho CH; Jung DI; Larock RC; Brown HA; Lindsley CW
    ACS Chem Biol; 2015 Feb; 10(2):421-32. PubMed ID: 25384256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-c.
    Sciorra VA; Hammond SM; Morris AJ
    Biochemistry; 2001 Feb; 40(8):2640-6. PubMed ID: 11327888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion.
    Burkhardt U; Beyer S; Klein J
    Eur J Pharmacol; 2015 Aug; 761():398-404. PubMed ID: 25967349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
    Scott SA; Selvy PE; Buck JR; Cho HP; Criswell TL; Thomas AL; Armstrong MD; Arteaga CL; Lindsley CW; Brown HA
    Nat Chem Biol; 2009 Feb; 5(2):108-17. PubMed ID: 19136975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of phospholipase D in osteoblast response to titanium surface microstructure.
    Fang M; Olivares-Navarrete R; Wieland M; Cochran DL; Boyan BD; Schwartz Z
    J Biomed Mater Res A; 2010 Jun; 93(3):897-909. PubMed ID: 19705469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of phospholipase D during cultured osteoblast mineralization and bone formation.
    Abdallah D; Skafi N; Hamade E; Borel M; Reibel S; Vitale N; El Jamal A; Bougault C; Laroche N; Vico L; Badran B; Hussein N; Magne D; Buchet R; Brizuela L; Mebarek S
    J Cell Biochem; 2019 Apr; 120(4):5923-5935. PubMed ID: 30320913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.
    O'Reilly MC; Scott SA; Brown KA; Oguin TH; Thomas PG; Daniels JS; Morrison R; Brown HA; Lindsley CW
    J Med Chem; 2013 Mar; 56(6):2695-9. PubMed ID: 23445448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.